{"entity":{"id":"nct06050122","kind":"trial","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","aka":[],"tldr":"A phase 3 trial of Patidegib Topical Gel in basal cell carcinoma, run by Sol-Gel Technologies, Ltd., now completed.","summary":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome is a phase 3 interventional study registered as NCT06050122 by Sol-Gel Technologies, Ltd., with 140 participants enrolled, started 2024-03-17 and reached its primary completion in 2026-08-20. Interventions recorded: Patidegib Topical Gel and Patidegib Topical Gel with no active patidegib.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06050122","url":"https://clinicaltrials.gov/study/NCT06050122"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["patidegib"],"companies":[],"institutions":[],"pathways":[],"terms":["hedgehog-inhibitor-tolerability"],"trials":["patidegib-gel-gorlin-phase-2","stevie"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Registry status on 22 September 2026: Completed (registry record last updated 18 September 2026; primary completion reached 20 August 2026)."],"nct":"NCT06050122","phase":"3","setting":"A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome","sponsor":"Sol-Gel Technologies, Ltd.","started":"2024-03-17","startedType":"actual","enrolled":140,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06050122/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/"}],"drug":[{"id":"patidegib","kind":"drug","name":"Patidegib","route":"/drugs/patidegib/"}],"term":[{"id":"hedgehog-inhibitor-tolerability","kind":"term","name":"Why people stop taking hedgehog inhibitors","route":"/terms/hedgehog-inhibitor-tolerability/"}],"trial":[{"id":"patidegib-gel-gorlin-phase-2","kind":"trial","name":"Patidegib gel in Gorlin syndrome (phase 2A)","route":"/trials/patidegib-gel-gorlin-phase-2/"},{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/"}]}}